Singh Ankur, Bryan Melanie M, Roney Joseph C, Cullinane Andrew R, Gahl William A, Khurana Nita, Kapoor Seema
Department of Pediatrics, Institute of Medical Sciences, Banaras Hindu University, Varanasi, India.
National Human Genome Research Institute, National Institutes of Health, Bethesda, MD, USA.
Int J Dermatol. 2016 Mar;55(3):317-21. doi: 10.1111/ijd.13019. Epub 2015 Oct 24.
Chediak-Higashi syndrome (CHS; OMIM no. 214500) is an inherited multisystem disorder presenting with hypopigmentation and a propensity to infections due to immunological dysfunction. CHS generally presents in infancy with a fatal outcome, but less severe cases can present in adulthood. Treatment with bone marrow transplantation can be life-saving, so establishing a correct diagnosis is critical. The presence of large granules on examination of peripheral blood smears is suggestive of the diagnosis of CHS in most centers. However, sequencing of the lysosomal trafficking, LYST, gene confirms the diagnosis and can provide a prognosis regarding disease severity. In the case presented here, we performed molecular testing to identify the causative mutation and tabulated published mutation data from 2009 to 2014. We found a novel frameshift mutation in our case and concluded that frameshift and nonsense are the most common types of mutation in CHS, but this may be biased due to underdiagnosis of the milder and atypical forms of the disease.
切迪阿克-希加希综合征(CHS;OMIM编号:214500)是一种遗传性多系统疾病,由于免疫功能障碍,表现为色素减退和易感染。CHS通常在婴儿期发病,预后不良,但病情较轻的病例也可能在成年期出现。骨髓移植治疗可能挽救生命,因此做出正确诊断至关重要。在大多数中心,外周血涂片检查发现大颗粒提示CHS诊断。然而,溶酶体运输调节蛋白(LYST)基因测序可确诊,并能提供疾病严重程度的预后信息。在此病例中,我们进行了分子检测以确定致病突变,并整理了2009年至2014年已发表的突变数据。我们在该病例中发现了一个新的移码突变,并得出结论,移码突变和无义突变是CHS最常见的突变类型,但这可能因疾病较轻和非典型形式的诊断不足而存在偏差。